Tumor necrosis factor inhibition and invasive fungal infections
- PMID: 15983902
- DOI: 10.1086/430000
Tumor necrosis factor inhibition and invasive fungal infections
Abstract
Candida albicans and Aspergillus fumigatus occur ubiquitously in nature; C. albicans is part of the natural flora of most healthy individuals, and A. fumigatus is commonly found in soil, plant debris, and indoor air. Neither fungus poses a threat to healthy individuals, but each can cause fatal infections in immunocompromised patients. The use of tumor necrosis factor (TNF) antagonists for the treatment of rheumatoid arthritis and other autoimmune diseases has been associated with an increased incidence of opportunistic infections, including infections with both of these fungi. Because the use of TNF antagonists is expected to increase in the future, understanding the role that TNF plays and the effect of its antagonism on host defense against infections with these fungi is critical for reducing the associated morbidity and mortality.
Similar articles
-
How to manage infections in the era of biologics?Dermatol Ther. 2008 May-Jun;21(3):180-6. doi: 10.1111/j.1529-8019.2008.00189.x. Dermatol Ther. 2008. PMID: 18564248 Review.
-
The impact of the host on fungal infections.Am J Med. 2012 Jan;125(1 Suppl):S39-51. doi: 10.1016/j.amjmed.2011.10.010. Am J Med. 2012. PMID: 22196208 Review.
-
Tumor necrosis factor inhibition and opportunistic infections.Clin Infect Dis. 2005 Aug 1;41 Suppl 3:S187-8. doi: 10.1086/429992. Clin Infect Dis. 2005. PMID: 15983897 No abstract available.
-
Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.Clin Microbiol Infect. 2006 Dec;12(12):1151-3. doi: 10.1111/j.1469-0691.2006.01546.x. Clin Microbiol Infect. 2006. PMID: 17121619
-
[Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports].Lakartidningen. 2005 Dec 5-11;102(49):3794-6, 3799-800. Lakartidningen. 2005. PMID: 16408703 Swedish.
Cited by
-
Adverse reactions to biologic agents and their medical management.Nat Rev Rheumatol. 2014 Oct;10(10):612-27. doi: 10.1038/nrrheum.2014.123. Epub 2014 Aug 12. Nat Rev Rheumatol. 2014. PMID: 25112605 Review.
-
Transforming growth factor-β1 sustains the survival of Foxp3(+) regulatory cells during late phase of oropharyngeal candidiasis infection.Mucosal Immunol. 2016 Jul;9(4):1015-26. doi: 10.1038/mi.2015.115. Epub 2015 Nov 4. Mucosal Immunol. 2016. PMID: 26530137 Free PMC article.
-
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.Arthritis Res Ther. 2017 Dec 22;19(1):285. doi: 10.1186/s13075-017-1490-y. Arthritis Res Ther. 2017. PMID: 29273067 Free PMC article. Clinical Trial.
-
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430. Ann Rheum Dis. 2007. PMID: 17934088 Free PMC article. Review. No abstract available.
-
IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans.J Immunol. 2015 Aug 1;195(3):780-8. doi: 10.4049/jimmunol.1500909. J Immunol. 2015. PMID: 26188072 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical